Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
Chemical and physical data | |
Formula | C25H26N2O |
Molar mass | 370.496 g·mol−1 |
3D model (JSmol) | |
| |
|
CUMYL-CB-MEGACLONE (CUMYL-CBMGACLONE, SGT-273) is a gamma-carboline based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first being identified in Hungary in April 2020.[1]
See also
References
Receptor (ligands) |
| ||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Transporter (modulators) |
| ||||||||||||||||||||||||||||||
Enzyme (modulators) |
| ||||||||||||||||||||||||||||||
Others |
| ||||||||||||||||||||||||||||||
|
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.